Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRIMSON: BI 764524 in Moderate to Severe Non-proliferative Diabetic Retinopathy
NCT06321302Phase 2Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- May 2024
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 2 trial of BI 764524, sponsored by Boehringer Ingelheim. Started May 2024; status: recruiting.
02
Drugs
BI 764524
Beyond the preview
Go deeper on NCT06321302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06321302.